Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

“Cost is a big issue for them as they want to produce on a large scale,” says Masuya. “Where they might need 50g of protein, they could do the same with 1-2g of peptide at a fraction of the ...

Del Campo says this line is a good option “for those seeking cost-effective and potent peptide formulations that are suitable even for sensitive skin.” Billed as an alternative to retinoids ...